Header Logo

Connection

PREETHI GUNARATNE to Cell Line, Tumor

Back to Details
This is a "connection" page, showing publications PREETHI GUNARATNE has written about Cell Line, Tumor.
PREETHI GUNARATNE
Connection Strength
0.753
Cell Line, Tumor
  1. MicroRNA-509-3p inhibits cellular migration, invasion, and proliferation, and sensitizes osteosarcoma to cisplatin. Sci Rep. 2019 12 13; 9(1):19089.
    View in: PubMed
    Score: 0.093
  2. Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors. Cancer. 2019 07 15; 125(14):2409-2422.
    View in: PubMed
    Score: 0.089
  3. miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. Oncotarget. 2016 May 03; 7(18):25930-48.
    View in: PubMed
    Score: 0.072
  4. A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells. Biomaterials. 2013 Jan; 34(3):807-16.
    View in: PubMed
    Score: 0.057
  5. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma. Cancer Res. 2011 Jun 01; 71(11):3841-51.
    View in: PubMed
    Score: 0.051
  6. Interactions between ADGRF1 (GPR110) and extracellular matrix proteins govern its effects on tumorigenesis in HER2-positive breast cancer. Br J Pharmacol. 2025 Jun; 182(11):2524-2541.
    View in: PubMed
    Score: 0.033
  7. HepT1-derived murine models of high-risk hepatoblastoma display vascular invasion, metastasis, and circulating tumor cells. Biol Open. 2022 09 15; 11(9).
    View in: PubMed
    Score: 0.028
  8. Pan-cancer analysis reveals TAp63-regulated oncogenic lncRNAs that promote cancer progression through AKT activation. Nat Commun. 2020 10 14; 11(1):5156.
    View in: PubMed
    Score: 0.025
  9. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat Immunol. 2019 07; 20(7):835-851.
    View in: PubMed
    Score: 0.022
  10. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Rep. 2018 04 03; 23(1):194-212.e6.
    View in: PubMed
    Score: 0.021
  11. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. Cell Rep. 2018 04 03; 23(1):297-312.e12.
    View in: PubMed
    Score: 0.021
  12. TAp63 suppresses mammary tumorigenesis through regulation of the Hippo pathway. Oncogene. 2017 04 27; 36(17):2377-2393.
    View in: PubMed
    Score: 0.019
  13. Tumour-suppressor microRNAs regulate ovarian cancer cell physical properties and invasive behaviour. Open Biol. 2016 11; 6(11).
    View in: PubMed
    Score: 0.019
  14. PPAR? agonists promote differentiation of cancer stem cells by restraining YAP transcriptional activity. Oncotarget. 2016 Sep 20; 7(38):60954-60970.
    View in: PubMed
    Score: 0.019
  15. ?Np63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. Cancer Cell. 2016 06 13; 29(6):874-888.
    View in: PubMed
    Score: 0.018
  16. Identification of potential glucocorticoid receptor therapeutic targets in multiple myeloma. Nucl Recept Signal. 2015; 13:e006.
    View in: PubMed
    Score: 0.018
  17. Single-Molecule Sequencing Reveals Estrogen-Regulated Clinically Relevant lncRNAs in Breast Cancer. Mol Endocrinol. 2015 Nov; 29(11):1634-45.
    View in: PubMed
    Score: 0.017
  18. Annexin A1 Preferentially Predicts Poor Prognosis of Basal-Like Breast Cancer Patients by Activating mTOR-S6 Signaling. PLoS One. 2015; 10(5):e0127678.
    View in: PubMed
    Score: 0.017
  19. IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo. Nature. 2015 Jan 29; 517(7536):626-30.
    View in: PubMed
    Score: 0.016
  20. Functional analysis of miR-34c as a putative tumor suppressor in high-grade serous ovarian cancer. Biol Reprod. 2014 Nov; 91(5):113.
    View in: PubMed
    Score: 0.016
  21. Identification of p38? as a therapeutic target for the treatment of S?zary syndrome. J Invest Dermatol. 2015 Feb; 135(2):599-608.
    View in: PubMed
    Score: 0.016
  22. G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic. Cancer Res. 2013 Jul 01; 73(13):4134-46.
    View in: PubMed
    Score: 0.015
  23. Novel MicroRNAs regulating proliferation and apoptosis in uterine papillary serous carcinomas. Cancer Lett. 2013 Jul 28; 335(2):314-22.
    View in: PubMed
    Score: 0.015
  24. Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. PLoS One. 2012; 7(3):e34546.
    View in: PubMed
    Score: 0.014
  25. MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase. Cancer Res. 2011 Feb 01; 71(3):645-54.
    View in: PubMed
    Score: 0.013
  26. A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol. 2010 Feb; 24(2):447-63.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.